MODIFICATION
65 -- 596-24-1-025-0002 - Radiopharmaceutical-LEX - FY24
- Notice Date
- 7/28/2023 1:56:31 PM
- Notice Type
- Solicitation
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- 249-NETWORK CONTRACT OFFICE 9 (36C249) MURFREESBORO TN 37129 USA
- ZIP Code
- 37129
- Solicitation Number
- 36C24923Q0449
- Response Due
- 8/18/2023 2:00:00 PM
- Archive Date
- 11/25/2023
- Point of Contact
- Martha Warren, Contract Specialist
- E-Mail Address
-
Martha.Warren1@va.gov
(Martha.Warren1@va.gov)
- Awardee
- null
- Description
- Description This is a solicitation for commercial products and commercial services prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, Streamlined Procedures for Evaluation and Solicitation for Commercial Products and Commercial Services, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested, and a written solicitation document will not be issued. This solicitation is issued as an RFQ. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC 2023-01, effective December 30, 2022. This solicitation is for Full and Open competition. The associated North American Industrial Classification System (NAICS) code for this procurement is 325412, with a small business size standard of 1,300 employees. The FSC/PSC is 6505. The Memphis VA Medical Center is seeking to purchase various radiopharmaceuticals for a Base period of 12 months plus four (4) 12-month options. All interested companies shall provide quotations for the following: Vendor MUST be able to provide ALL items in order to be determined responsive. All quantities are ESTIMATED. Supplies/Services Item Number Description ESTIMATED Quantity Unit of Measure Unit Price Extended Price 0001 F-18 FDG 10mCi 400 EA 0002 Ga-67 (per mCi) 6 EA 0003 I-123 200uCi Uptake Caps 12 EA 0004 I-131 Diagnostic Cap (5mCi) 20 EA 0005 I-131 Therapeutic dose (per mCi) physician ordered 1200 EA 0006 I-131 Uptake Caps .02mCi 1 EA 0007 In-111 Octreoscan (pentatreotide) 6mCi 2 EA 0008 In-111 WBC Kit/Labeling 1mCi 1 EA 0009 PYP Vial 15 EA 0010 Kinevac (CCK) 50 EA 0011 Tc-99m Exametazime * 25mCi 1 EA 0012 Tc-99m HMPAO WBC Kit/Labeling 20mCi 1 EA 0013 Tc-99m Macroaggregated Albumin (MAA) 3mCi 25 EA 0014 Tc-99m Mebrofenin (Choletec) 5mCi 50 EA 0015 Tc-99m Medronate (MDP) 25mCi 250 EA 0016 Tc-99m MAG3 (mertiatide) 6mCi 30 EA 0017 Tc-99m Pentetate (DTPA) 30mCi 30 EA 0018 Tc-99m pyrophosphate (Hot PYP) 20mCi 15 EA 0019 Tc-99m sestamibi 25mCi 50 EA 0020 Tc-99m sodium pertechnetate (TcO4) 20mCi 90 EA 0021 Tc-99m sulfur colloid dmCi 50 EA 0022 Tc-99m sulfur colloid filtered 1mCi 1 EA 0023 Tc-99m TcO4 LINEARITY SOURCE 300mCi 4 EA 0024 Tc-99m Myoview 15mCi 1500 EA 0025 Tl-201 (per mCi) 4mCi 16 EA 0026 Tc-99m UltraTag Kit 1 EA 0027 Hot Lab Management Software 1 EA 1001 F-18 FDG 10mCi 400 EA 1002 Ga-67 (per mCi) 6 EA 1003 I-123 200uCi Uptake Caps 12 EA 1004 I-131 Diagnostic Cap (5mCi) 20 EA 1005 I-131 Therapeutic dose (per mCi) physician ordered 1200 EA 1006 I-131 Uptake Caps .02mCi 1 EA 1007 In-111 Octreoscan (pentatreotide) 6mCi 2 EA 1008 In-111 WBC Kit/Labeling 1mCi 1 EA 1009 PYP Vial 15 EA 1010 Kinevac (CCK) 50 EA 1011 Tc-99m Exametazime * 25mCi 1 EA 1012 Tc-99m HMPAO WBC Kit/Labeling 20mCi 1 EA 1013 Tc-99m Macroaggregated Albumin (MAA) 3mCi 25 EA 1014 Tc-99m Mebrofenin (Choletec) 5mCi 50 EA 1015 Tc-99m Medronate (MDP) 25mCi 250 EA 1016 Tc-99m MAG3 (mertiatide) 6mCi 30 EA 1017 Tc-99m Pentetate (DTPA) 30mCi 30 EA 1018 Tc-99m pyrophosphate (Hot PYP) 20mCi 15 EA 1019 Tc-99m sestamibi 25mCi 50 EA 1020 Tc-99m sodium pertechnetate (TcO4) 20mCi 90 EA 1021 Tc-99m sulfur colloid dmCi 50 EA 1022 Tc-99m sulfur colloid filtered 1mCi 1 EA 1023 Tc-99m TcO4 LINEARITY SOURCE 300mCi 4 EA 1024 Tc-99m Myoview 15mCi 1500 EA 1025 Tl-201 (per mCi) 4mCi 16 EA 1026 Tc-99m UltraTag Kit 1 EA 1027 Hot Lab Management Software 1 EA 2001 F-18 FDG 10mCi 400 EA 2002 Ga-67 (per mCi) 6 EA 2003 I-123 200uCi Uptake Caps 12 EA 2004 I-131 Diagnostic Cap (5mCi) 20 EA 2005 I-131 Therapeutic dose (per mCi) physician ordered 1200 EA 2006 I-131 Uptake Caps .02mCi 1 EA 2007 In-111 Octreoscan (pentatreotide) 6mCi 2 EA 2008 In-111 WBC Kit/Labeling 1mCi 1 EA 2009 PYP Vial 15 EA 2010 Kinevac (CCK) 50 EA 2011 Tc-99m Exametazime * 25mCi 1 EA 2012 Tc-99m HMPAO WBC Kit/Labeling 20mCi 1 EA 2013 Tc-99m Macroaggregated Albumin (MAA) 3mCi 25 EA 2014 Tc-99m Mebrofenin (Choletec) 5mCi 50 EA 2015 Tc-99m Medronate (MDP) 25mCi 250 EA 2016 Tc-99m MAG3 (mertiatide) 6mCi 30 EA 2017 Tc-99m Pentetate (DTPA) 30mCi 30 EA 2018 Tc-99m pyrophosphate (Hot PYP) 20mCi 15 EA 2019 Tc-99m sestamibi 25mCi 50 EA 2020 Tc-99m sodium pertechnetate (TcO4) 20mCi 90 EA 2021 Tc-99m sulfur colloid dmCi 50 EA 2022 Tc-99m sulfur colloid filtered 1mCi 1 EA 2023 Tc-99m TcO4 LINEARITY SOURCE 300mCi 4 EA 2024 Tc-99m Myoview 15mCi 1500 EA 2025 Tl-201 (per mCi) 4mCi 16 EA 2026 Tc-99m UltraTag Kit 1 EA 2027 Hot Lab Management Software 1 EA 3001 F-18 FDG 10mCi 400 EA 3002 Ga-67 (per mCi) 6 EA 3003 I-123 200uCi Uptake Caps 12 EA 3004 I-131 Diagnostic Cap (5mCi) 20 EA 3005 I-131 Therapeutic dose (per mCi) physician ordered 1200 EA 3006 I-131 Uptake Caps .02mCi 1 EA 3007 In-111 Octreoscan (pentatreotide) 6mCi 2 EA 3008 In-111 WBC Kit/Labeling 1mCi 1 EA 3009 PYP Vial 15 EA 3010 Kinevac (CCK) 50 EA 3011 Tc-99m Exametazime * 25mCi 1 EA 3012 Tc-99m HMPAO WBC Kit/Labeling 20mCi 1 EA 3013 Tc-99m Macroaggregated Albumin (MAA) 3mCi 25 EA 3014 Tc-99m Mebrofenin (Choletec) 5mCi 50 EA 3015 Tc-99m Medronate (MDP) 25mCi 250 EA 3016 Tc-99m MAG3 (mertiatide) 6mCi 30 EA 3017 Tc-99m Pentetate (DTPA) 30mCi 30 EA 3018 Tc-99m pyrophosphate (Hot PYP) 20mCi 15 EA 3019 Tc-99m sestamibi 25mCi 50 EA 3020 Tc-99m sodium pertechnetate (TcO4) 20mCi 90 EA 3021 Tc-99m sulfur colloid dmCi 50 EA 3022 Tc-99m sulfur colloid filtered 1mCi 1 EA 3023 Tc-99m TcO4 LINEARITY SOURCE 300mCi 4 EA 3024 Tc-99m Myoview 15mCi 1500 EA 3025 Tl-201 (per mCi) 4mCi 16 EA 3026 Tc-99m UltraTag Kit 1 EA 3027 Hot Lab Management Software 1 EA 4001 F-18 FDG 10mCi 400 EA 4002 Ga-67 (per mCi) 6 EA 4003 I-123 200uCi Uptake Caps 12 EA 4004 I-131 Diagnostic Cap (5mCi) 20 EA 4005 I-131 Therapeutic dose (per mCi) physician ordered 1200 EA 4006 I-131 Uptake Caps .02mCi 1 EA 4007 In-111 Octreoscan (pentatreotide) 6mCi 2 EA 4008 In-111 WBC Kit/Labeling 1mCi 1 EA 4009 PYP Vial 15 EA 4010 Kinevac (CCK) 50 EA 4011 Tc-99m Exametazime * 25mCi 1 EA 4012 Tc-99m HMPAO WBC Kit/Labeling 20mCi 1 EA 4013 Tc-99m Macroaggregated Albumin (MAA) 3mCi 25 EA 4014 Tc-99m Mebrofenin (Choletec) 5mCi 50 EA 4015 Tc-99m Medronate (MDP) 25mCi 250 EA 4016 Tc-99m MAG3 (mertiatide) 6mCi 30 EA 4017 Tc-99m Pentetate (DTPA) 30mCi 30 EA 4018 Tc-99m pyrophosphate (Hot PYP) 20mCi 15 EA 4019 Tc-99m sestamibi 25mCi 50 EA 4020 Tc-99m sodium pertechnetate (TcO4) 20mCi 90 EA 4021 Tc-99m sulfur colloid dmCi 50 EA 4022 Tc-99m sulfur colloid filtered 1mCi 1 EA 4023 Tc-99m TcO4 LINEARITY SOURCE 300mCi 4 EA 4024 Tc-99m Myoview 15mCi 1500 EA 4025 Tl-201 (per mCi) 4mCi 16 EA 4026 Tc-99m UltraTag Kit 1 EA 4027 Hot Lab Management Software 1 EA Total All quoters shall submit the following: Technical or Quality: Provide the extent to which the proposed item(s) can meet and/or exceed the Government s requirements as outlined in the solicitation and based on the information requested in the instructions to quoters section of the solicitation. Past Performance: Provide verifiable past performance evaluations - minimum of 2, maximum of 3 - of similar contracts performed. The past performance evaluation will assess the relative risks associated with a quoter s likelihood of success in fulfilling the solicitation s requirements as indicated by the quoter s record of past performance. The past performance evaluation may be based on the contracting officer s knowledge of and previous experience with the supply or service being acquired; Customer surveys, and past performance questionnaire replies; Contractor Performance Assessment Reporting System (CPARS) at http://www.cpars.gov/; or any other reasonable basis. Price: The Government will evaluate the price by adding the total of all line item prices. -Options. The Government will evaluate quotations for award purposes by adding the total price for all options to the total price for the basic requirement. This includes options under FAR 52.217-8, Option to Extend Services, which applies to this solicitation. Evaluation of options under FAR 52.217-8 will be accomplished by adding six months of the quoter's price for the last potential period of performance under this contract to the quoter's total price. For example, if the contract includes option periods that are exercisable under FAR 52.217-9, the quoter's total price for the purpose of evaluation will include the base period, all option periods, and an additional six months of the last option period. Quoters must price only the base and option periods specified in the contract line item numbers (CLINs), and shall not submit a price for the potential six-month extension of services under FAR 52.217-8. The Government reserves the right to exercise the option under FAR 52.217-8 before the end of any of the contractor's performance periods and will be exercised at the price and/or rates in effect at the time the clause is exercised. Evaluation of options shall not obligate the Government to exercise the option(s). -36C24923Q0449 Line Item Spreadsheet (attached) with all columns highlighted in yellow completed. All quotes shall be sent to Martha.Warren1@va.gov. Award will be based upon a comparative evaluation of quotes in accordance with the Simplified Acquisition Procedures of FAR 13. Comparative evaluation is the side by side pairwise comparison of quotes based on factors resulting in a Contracting Officer decision for the quote most favorable to the Government. The award will be made to the response most advantageous to the Government. Responses should contain your best terms, conditions. Additional Solicitation Terms and Conditions. This is a Full and Open Competition solicitation. This RFQ closes August 18, 2023, at 16:00 CDT. Submit all quotes and applicable attachments by e-mail to martha.warren1@va.gov with subject line RFQ 36C24923Q0449 Radiopharmaceuticals-LEX by Friday, August 18, 2023, at 16:00 hours (CDT). Final Offer package will be put into attachments and emailed to martha.warren1@va.gov. Multiple emails will not be accepted. Our email server has a size limitation of 30 GB. Zip files will be removed and therefore, will not be considered. Email attachment must be in .pdf format and in the English language. Font type & size must be appropriate for easy and quick viewing, 10 point or greater. Only acceptable font types are Calibri, Times New Roman, Courier, or Arial. Documents must only be 8 ½ x 10 inches in size, with one-inch margins all around. Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). Must include offer s UEI Unique Entity Identification To facilitate the award process, all quotes must include a statement regarding the terms and conditions herein as follows: ""The terms and conditions in the solicitation are acceptable to be included in the award document without modification, deletion, or addition."" OR ""The terms and conditions in the solicitation are acceptable to be included in the award document with the exception, deletion, or addition of the following:"" Quoter shall list exception(s) and rationale for the exception(s). Phone calls and fax will not be accepted, all questions or concerns must be submitted via email to martha.warren1@va.gov, with subject line Questions- RFQ 36C24923Q0449 Radiopharmaceuticals-LEX by Friday, August 11, 2023, at 16:00 hours (CDT). The Government reserves the right to make no award at all.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/1a5ef08b679145e6bed4d0a7d802548e/view)
- Record
- SN06767817-F 20230730/230728230045 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |